TNFSF10 and myeloid sarcoma: It is evident that these two “sides” of TRAIL, anti-inflammatory and pro-apoptotic, could be targeted differently for the same therapeutic purpose in EAE/MS, and, indeed, the therapeutic potential of targeting the TRAIL system to manage EAE has recently been explored using different approaches.